**Department of Ophthalmology**

**Federal University of São Paulo**

Jnuary, 24th 2013

Dear Editor,

Please find enclosed the full-text manuscript in Word format (file name Bevacizumab for DME.docx).

**Title:** Bevacizumab for the Management of Diabetic Macular Edema.

**Author:** Francisco Rosa Stefanini1, MD; J. Fernando Arevalo MD, FACS; Maurício Maia, MD, PhD

**Manuscript No:** 892

The manuscript has been improved according to the suggestions of reviewers. Response to Reviewers' comments:

Reviewer #00132581: The authors might consider to add to de following reference: Simo R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51(9):1574-80.

Answer: We agree with the reviewers and this reference was included (number 19) in order to increase scientific basis to statement of paragraph initiate in page 4, line 15: “VEGF expression and signaling are deregulated in diabetic retinopathy, and VEGF is an important mediator of blood retinal barrier breakdown, leading to fluid leakage to the macula and the development of macular edema. Therefore, at present, treatment with anti-VEGF is one of the most promising approaches for the treatment of visual loss due to DME”.

Moreover, we included the following sentence based in this reference (page 12, line 22): Although delivered intravitreous, anti-VEGF drugs could get acess to the systemic circulation”.

Sincerely yours,

Francisco Stefanini, MD (First and Corresponding Author)

Department of Ophthalmology

Federal University of Sao Paulo, Sao Paulo, Brazil

Phone: 55-11-981453897

[franstefanini@yahoo.com.br](mailto:badarojf@yahoo.com.br)